Should you build or buy Electronic Data Capture (EDC)?
Electronic Data Capture software is where clinical trial sites enter patient data into structured case report forms, replacing paper charts with an audit-trailed, validated database. It runs edit checks, query management and exports formatted for regulatory submission. Buyers are pharmaceutical sponsors, biotech companies, academic medical centers and the CROs that run trials for them.
Buy a supported commercial EDC for commercial, registrational or multinational trials and for anything needing integrated RTSM, ePRO or eConsent. Use institutional REDCap or open-source EDC for appropriately scoped academic or investigator-initiated studies where the institution has a validated pathway and can sustain study-level documentation. Build custom only with a durable product and quality-system team ready to own the full software lifecycle under FDA guidance.
Build it, buy it, or bridge?
When building makes sense
Free and open-source EDC has a real place, but it belongs to institutions, not commercial sponsors chasing an approval. OpenClinica's own site draws a hard line here: its cloud-hosted product is validated and compliant with Part 11, GCP and HIPAA, and it says plainly that its free community edition does not carry those features. That is not marketing caution, it is the actual gap between a free download and a system an inspector will accept for a registrational trial. A university running an investigator-initiated study, with its own institutional review process and staff who can sustain study-level validation documentation over years, is the credible build case. A commercial sponsor with no in-house quality system, planning a trial that will face an FDA or EMA inspection, is taking on a validation burden that has no shortcut and no vendor to blame when it falls short.
When buying makes sense
Buying a commercial EDC earns its keep the moment a trial is commercial, multinational or headed toward regulatory submission. Vendors sell the validated release, the audit trail, and increasingly the integrated randomization, ePRO and eConsent modules an inspector expects to see working together. That bundling is the real product: a sponsor rebuilding query management, coding and CDISC exports from scratch is redoing work every commercial EDC already ships. The buy case gets stronger with trial complexity, since a global Phase III with dozens of sites has no institutional home to absorb ongoing validation the way a university does. Even a smaller sponsor should buy rather than assemble a system for a single registrational study, because the vendor spreads its validation cost across every customer and every trial, and a one-off sponsor cannot.
The desk read
Build-versus-buy analysis for Electronic Data Capture (EDC) is being written. In the meantime, the framework that drives every B4 call is on the B4 Index page.
Frequently asked
Can a hospital or university legally run a trial on free EDC software?
Yes, within the institution's own governance. Several academic centers run REDCap or open-source EDC under institutional Part 11 programs for investigator-initiated studies, with the university's quality system standing in for a vendor's validation package. That model works because the institution, not a single research team, owns the ongoing compliance burden.
What does OpenClinica itself say about its free version?
Its own site distinguishes the cloud-hosted product, which it calls validated and Part 11, GCP and HIPAA compliant, from the free community edition, which does not carry a drag-and-drop study designer or the same feature set. That is the vendor's own line between a hobby install and a system meant for regulated work.
Does CDISC standardization mean every trial's EDC build looks the same?
The case report form shape is standardized through CDASH and CDISC, but each protocol still needs its own endpoints, visit schedule, eligibility logic and integrations built on top. The toolkit is shared; the configuration for any specific trial is not.
Is AI closing the gap between free and commercial EDC?
It is narrowing the form-building and query-drafting work on both sides, but it has no bearing on the validation documentation an inspector wants to see. That gap is procedural, not technical, so AI speeds up either path without erasing the difference between them.